Marine Drugs (Jan 2023)

New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide

  • Sergey A. Dyshlovoy,
  • Olesya I. Zhuravleva,
  • Jessica Hauschild,
  • Tobias Busenbender,
  • Dmitry N. Pelageev,
  • Anton N. Yurchenko,
  • Yuliya V. Khudyakova,
  • Alexandr S. Antonov,
  • Markus Graefen,
  • Carsten Bokemeyer,
  • Gunhild von Amsberg

DOI
https://doi.org/10.3390/md21010054
Journal volume & issue
Vol. 21, no. 1
p. 54

Abstract

Read online

Marine fungi serve as a valuable source for new bioactive molecules bearing various biological activities. In this study, we report on the isolation of a new indole diketopiperazine alkaloid deoxy-14,15-dehydroisoaustamide (1) from the marine-derived fungus Penicillium dimorphosporum KMM 4689 associated with a soft coral. The structure of this metabolite, including its absolute configuration, was determined by HR-MS, 1D and 2D NMR as well as CD data. Compound 1 is a very first deoxyisoaustamide alkaloid possessing two double bonds in the proline ring. The isolated compound was noncytotoxic to a panel of human normal and cancer cell lines up to 100 µM. At the same time, compound 1 resensitized prostate cancer 22Rv1 cells to androgen receptor (AR) blocker enzalutamide. The mechanism of this phenomenon was identified as specific drug-induced degradation of androgen receptor transcription variant V7 (AR-V7), which also resulted in general suppression of AR signaling. Our data suggest that the isolated alkaloid is a promising candidate for combinational therapy of castration resistant prostate cancer, including drug-resistant subtypes.

Keywords